Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Post time 6 hour(s) ago

journal：New England Journal of Medicine

Authors：Julio Rosenstock; Stanley Hsia; Luis Nevarez Ruiz; Sarah Eyde; David Cox; Wen-Shuo Wu; Rong Liu; Jianghao Li; Laura Fernández Landó; Max Denning; Lisa Ludwig; Yanyun Chen

Published date：2025-9-18

DOI：10.1056/nejmoa2505669

PDF link：http://www.nejm.org/doi/pdf/10.1056/NEJMoa2505669

Article link：https://doi.org/10.1056/nejmoa2505669

Article Source：Massachusetts Medical Society。

Remark：

Post time 6 hour(s) ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[NEJM] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes